摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2(S)-(L-histidyl)amino-1-cyclohexyl-3(S)-hydroxy-6-methylheptane | 120377-10-8

中文名称
——
中文别名
——
英文名称
2(S)-(L-histidyl)amino-1-cyclohexyl-3(S)-hydroxy-6-methylheptane
英文别名
(2S)-2-amino-N-[(2S,3S)-1-cyclohexyl-3-hydroxy-6-methylheptan-2-yl]-3-(1H-imidazol-5-yl)propanamide
2(S)-(L-histidyl)amino-1-cyclohexyl-3(S)-hydroxy-6-methylheptane化学式
CAS
120377-10-8
化学式
C20H36N4O2
mdl
——
分子量
364.531
InChiKey
RTDWRWREHURXGK-FHWLQOOXSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    26
  • 可旋转键数:
    10
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.8
  • 拓扑面积:
    104
  • 氢给体数:
    4
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    2(S)-(L-histidyl)amino-1-cyclohexyl-3(S)-hydroxy-6-methylheptane 生成 (2S)-2-benzyl-N-[(2S)-1-[[(2S,3S)-1-cyclohexyl-3-hydroxy-6-methylheptan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-4-oxo-4-pyridin-3-ylbutanamide
    参考文献:
    名称:
    XEHMMI, KEHJDZI;KATSURA, MASAXIRO;IMAI, XIROSUKEH;KAYAKIRI, NATSUKO;XASIM+
    摘要:
    DOI:
  • 作为产物:
    描述:
    2(S)-(N-t-butoxycarbonyl-L-histidyl)amino-1-cyclohexyl-3(S)-hydroxy-6-methylheptane 以 乙酸乙酯三氟乙酸 为溶剂, 生成 2(S)-(L-histidyl)amino-1-cyclohexyl-3(S)-hydroxy-6-methylheptane
    参考文献:
    名称:
    Renin inhibitor peptide compounds, a process for the preparation thereof
    摘要:
    该化合物的结构式为:##STR1##其中R.sup.1为芳基,可选择地取代为卤素和卤代(低)烷基;低烷基或环(低)烷基;R.sup.2为氢或低烷基,或R.sup.1和R.sup.2与连接的氮原子一起形成一个杂环基,可选择地取代为低烷基和酯化羧基;R.sup.3为氢或低烷基,R.sup.4为低烷基,以及其药学上可接受的盐,制备方法和包含该化合物的药物组合物。
    公开号:
    US04963530A1
点击查看最新优质反应信息

文献信息

  • New Histidyl amino acid derivatives, and pharmaceutical composition
    申请人:Fujisawa Pharmaceutical Co., Ltd.
    公开号:US04921855A1
    公开(公告)日:1990-05-01
    A compound of the formula: ##STR1## wherein R.sup.1 is lower alkyl optionally substituted with a substituent selected from the group consisting of acyl, hydroxy, lower alkoxy, aryl, lower alkylthio and a group of the formula: ##STR2## in which R.sup.5 is hydrogen or acyl and R.sup.6 is hydrogen or lower alkyl; aryl; or amino optionally substituted with substituent(s) selected from the group consisting of lower alkyl and acyl; and R.sup.2 is hydrogen or lower alkyl; or R.sup.1 and R.sup.2 are taken together with the attached nitrogen atom to form a heterocyclic group optionally substituted with substituent(s) selected from the group consisting of lower alkyl, hydroxy(lower )alkyl, lower alkoxy(lower)alkyl, acyl(lower)alkyl, oxo and acyl; R.sup.3 is hydrogen or lower alkyl; and R.sup.4 is lower alkyl; and its pharmaceutically acceptable salt, processes for the preparation thereof and pharmaceutical composition comprising the same.
    一种化合物的化学式如下:##STR1## 其中R.sup.1是较低的烷基,可选择性地被选自以下群组的取代基取代,所述群组包括酰基、羟基、较低的烷氧基、芳基、较低的烷基硫基和化学式为:##STR2## 其中R.sup.5是氢或酰基,R.sup.6是氢或较低的烷基;芳基;或氨基,可选择性地被选自以下群组的取代基取代,所述群组包括较低的烷基和酰基;R.sup.2是氢或较低的烷基;或R.sup.1和R.sup.2与所连接的氮原子一起形成杂环基,可选择性地被选自以下群组的取代基取代,所述群组包括较低的烷基、羟基(较低的)烷基、较低的烷氧基(较低的)烷基、酰基(较低的)烷基、氧代和酰基;R.sup.3是氢或较低的烷基;R.sup.4是较低的烷基;以及其药学上可接受的盐,其制备方法和包含其的制药组合物。
  • Amino acid derivatives, processes for the preparation thereof and
    申请人:Ujisawa Pharmaceutical Co., Ltd.
    公开号:US05223489A1
    公开(公告)日:1993-06-29
    A compound of the formula: ##STR1## wherein R.sup.1 is lower alkyl optionally substituted aryl; or amino optionally substituted; and R.sup.2 is hydrogen or lower alkyl; or R.sup.1 and R.sup.2 are taken together with the attached nitrogen atom to form a heterocyclic group optionally substituted; R.sup.3 is hydrogen or lower alkyl; and R.sup.4 is lower alkyl; and its pharmaceutically acceptable salt, processes for the preparation thereof and pharmaceutical composition comprising the same
    一种化合物的公式:##STR1##其中R.sup.1是低碳基可选择取代芳基; 或氨基可选择取代; R.sup.2是氢或低碳基; 或R.sup.1和R.sup.2与所连接的氮原子一起形成可选择取代的杂环基团; R.sup.3是氢或低碳基; R.sup.4是低碳基; 以及其药学上可接受的盐,其制备方法和包含该化合物的药物组成物。
  • Intermediate for preparation of amino acid derivatives
    申请人:Fujisawa Pharmaceutical Company, Ltd.
    公开号:US05142048A1
    公开(公告)日:1992-08-25
    The invention relates to novel intermediate compounds for preparation of novel amino acid derivatives having renin inhibiting activity.
    本发明涉及用于制备具有肾素抑制活性的新型氨基酸衍生物的新型中间体化合物。
  • New peptide compounds, a process for the preparation thereof and pharmaceutical composition comprising the same
    申请人:FUJISAWA PHARMACEUTICAL CO., LTD.
    公开号:EP0283970A2
    公开(公告)日:1988-09-28
    A compound of the formula : wherein R1 is aryl optionally substituted with a substituent selected from the group consisting of halogen and halo(lower)alkyl; lower alkyl or cyclo(lower)alkyl; and R2 is hydrogen or lower alkyl, or R' and R2 are taken together with the attached nitrogen atom to form a heterocylic group optionally substituted with a substituent selected from the group consisting of lower alkyl and esterified carboxy, R3 is hydrogen or lower alkyl, and R4 is lower alkyl, and its pharmaceutically acceptable salt, a process for the preparation thereof and pharmaceutical composition comprising the same
    式中的化合物: 其中 R1 是芳基,可任选被选自由卤素和卤代(低级)烷基组成的取代基取代; 低级烷基或环(低级)烷基;以及 R2 是氢或低级烷基,或 R' 和 R2 与相连的氮原子一起形成杂环基团,该杂环基团可选择被选自低 级烷基和酯化羧基的取代基取代、 R3 是氢或低级烷基,以及 R4 是低级烷基、 及其药学上可接受的盐、其制备方法和包含其的药物组合物
  • New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
    申请人:FUJISAWA PHARMACEUTICAL CO., LTD.
    公开号:EP0300189A2
    公开(公告)日:1989-01-25
    A compound of the formula : wherein R1 is lower alkyl optionally substituted with a substituent selected from the group consisting of acyl,hydroxy, lower alkoxy, aryl, lower alkylthio and a group of the formula : in which R5 is hydrogen or acyl and R6 is hydrogen or lower alkyl; aryl; or amino optionally substituted with substituent(s) selected from the group consisting of lower alkyl and acyl; and R2 is hydrogen or lower alkyl; or R1 and R2 are taken together with the attached nitrogen atom to form a heterocyclic group optionally substituted with substituent(s) selected from the group consisting of lower alkyl, hydroxy(lower)alkyl, lower alkoxy(lower)alkyl, acyl(lower)alkyl, oxo and acyl; R3 is hydrogen or lower alkyl; and R4 is lower alkyl; and its pharmaceutically acceptable salt, processes for the preparation thereof and pharmaceutical composition comprising the same.
    一种式如下的化合物 其中 R1 是低级烷基,可任选被选自以下组别的取代基取代:酰基、羟基、低级烷氧基、芳基、低级烷硫基和一个式......的基团: 其中 R5 为氢或酰基,且 R6 是氢或低级烷基;芳基;或被选自低级烷基和酰基的取代基任选取代的氨基;以及 R2 是氢或低级烷基;或 R1 和 R2 与所连接的氮原子一起形成杂环基团,该杂环基团可任选被选自由低级烷基、羟基(低级)烷基、低级烷氧基(低级)烷基、酰基(低级)烷基、氧代和酰基组成的取代基取代; R3 是氢或低级烷基;和 R4 是低级烷基; 及其药学上可接受的盐、制备工艺和包含这些成分的药物组合物。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物